Sensorion Valuation

Is RFM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RFM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RFM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RFM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RFM?

Key metric: As RFM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RFM. This is calculated by dividing RFM's market cap by their current revenue.
What is RFM's PS Ratio?
PS Ratio	36.3x
Sales	€5.57m
Market Cap	€202.25m

RFM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	30.2x
Enterprise Value/EBITDA	-7.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RFM's PS Ratio compare to its peers?

The above table shows the PS ratio for RFM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.9x
HPHA Heidelberg Pharma	12.3x	16.6%	€103.9m
FYB Formycon	13.6x	33.4%	€827.2m
BIO3 Biotest	1.5x	3.6%	€1.4b
2INV 2invest	8.2x	n/a	€63.8m
RFM Sensorion	36.3x	44.9%	€202.3m

Price-To-Sales vs Peers: RFM is expensive based on its Price-To-Sales Ratio (36.3x) compared to the peer average (8.2x).

Price to Sales Ratio vs Industry

How does RFM's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RFM is expensive based on its Price-To-Sales Ratio (36.3x) compared to the European Biotechs industry average (9.8x).

Price to Sales Ratio vs Fair Ratio

What is RFM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RFM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	36.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RFM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

-4.3%

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

5.1%

22.9%